Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 7/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112277 | 0.85 | HSD11B1 (0.38) | DPP4HSD11B1 | |
| SCHEMBL10112658 | 0.85 | SLC6A2 (0.41) | DPP4HSD11B1CYP2C9 | |
| SCHEMBL12967842 | 0.74 | SLC6A3 (0.49) | — | |
| SCHEMBL28750424 | 0.70 | SLC6A3 (0.41) | — | |
| SCHEMBL29926647 | 0.68 | DPP4 (0.45) | DPP4DPP8DPP9PARP1 | |
| SCHEMBL10122799 | 0.68 | CHRNB4 (0.39) | CYP2C9 | |
| SCHEMBL28171776 | 0.64 | KCNH2 (0.44) | — | |
| SCHEMBL22443612 | 0.64 | SLC6A3 (0.39) | — | |
| SCHEMBL22443567 | 0.63 | HTR2A (0.40) | — | |
| SCHEMBL22443660 | 0.63 | HTR2A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012135749-A2 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012088254-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2011130654-A1 | FOX03A AS PREDICTIVE BIOMARKER FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2011-10-20 | — | — | WO | disclosed |